Pinned Tweet
Excited about our new paper! Incredibly innovative conceptual development from brilliant former post-doc @augelloma, with incredibly talented post-doc Xuanrong Chen moving it forward and getting it over the finish line 1/N
nature.com/articles/s4146…
nature.com/articles/s4146…
6
24
118
11,673
Chris Barbieri retweeted
Very excited to be a candidate for the @ASCO Board surgical oncology seat. Visit asco.org/election to learn more about the candidates and cast your vote!
3
23
107
5,030
Chris Barbieri retweeted
The doctors will get an Epic query asking them whether it was an Ordinary Mass, Solemn Mass, or ‘Mass, Undetermined’.
Then another one reminding them to use the Papal Mass order set, and a chat message asking them to put an order in for the green vestment.
Then another one reminding them to use the Papal Mass order set, and a chat message asking them to put an order in for the green vestment.
Pope Leo XIV celebrated Mass at noon on Friday in the room set up on the 10th floor of Gemelli Hospital, according to the Holy See Press Office.
Several members of Gemelli's medical and nursing staff attended the Mass, along with members of the Vatican City State Gendarmerie the Pope thanked all the staff—doctors, nurses, and orderlies—for the work they do every day caring for patients in their frailty, and especially for what they have done and continue to do for him," read the statement.
10
7
123
7,421
Chris Barbieri retweeted
@VickersBiostats @BehfarEhdaieMD @KristineLacuna @drthomaskole @rovingatuscap @DanielGorovets @wandering_gu Starting off Day 2 with a bang. @Chris_Barbieri1 with a tour de force seminar on AR biology and molecular subtypes to translate biology to clinical action.
1
1
6
248
Chris Barbieri retweeted
Important data from the UK HEAT and ICE registries on focal therapy for localized prostate cancer—and an important discussion about what these data can (and cannot) tell us.
Our response in @EUplatinum 👇
sciencedirect.com/science/articl…
Our response in @EUplatinum 👇
sciencedirect.com/science/articl…
1
7
20
6,399
Chris Barbieri retweeted
Our latest in @JAMAOnc prebiopsy MRI is now used in ~2/3 of US prostate biopsies.
Up sharply since 2017 but still work to do.
With Stephen Rhodes and coauthors @SBasourakos @jimhumd @Chris_Barbieri1 @angela_jia_ @Soum_Roy_RadOnc @DrSpratticus @LPonsky
@CaseUrology @UHhospitals cc
jamanetwork.com/journals/jamao…
Up sharply since 2017 but still work to do.
With Stephen Rhodes and coauthors @SBasourakos @jimhumd @Chris_Barbieri1 @angela_jia_ @Soum_Roy_RadOnc @DrSpratticus @LPonsky
@CaseUrology @UHhospitals cc
jamanetwork.com/journals/jamao…
6
17
44
9,250
Chris Barbieri retweeted
New study with our amazing partners showing calorie restriction reduces aging associated mutation accumulation in mice is out in @CellCellPress.
While lots of interventions increase mutations, here we show CR can actually slow normal aging-associated mutations genome-wide!
Remarkable linkage between diet, genomic integrity, and lifespan.
Interestingly, benefits were not uniformly distributed across the genome.
cell.com/cell/abstract/…
Led by @ShoagLab @giladevrony @VickyAcostaR @CircadianClocks @GronskaPeski @greenlab_utsw
cc @PeterAttiaMD @NirBarzilaiMD @agingdoc1 @aubreydegrey @CharlesMBrenner @mkaeberlein @davidasinclair @UH_RE_Institute @caseccc @CaseUrology
While lots of interventions increase mutations, here we show CR can actually slow normal aging-associated mutations genome-wide!
Remarkable linkage between diet, genomic integrity, and lifespan.
Interestingly, benefits were not uniformly distributed across the genome.
cell.com/cell/abstract/…
Led by @ShoagLab @giladevrony @VickyAcostaR @CircadianClocks @GronskaPeski @greenlab_utsw
cc @PeterAttiaMD @NirBarzilaiMD @agingdoc1 @aubreydegrey @CharlesMBrenner @mkaeberlein @davidasinclair @UH_RE_Institute @caseccc @CaseUrology
1
11
20
1,783
Chris Barbieri retweeted
This #ProstateCancerAwarenessMonth, we invite all patients and loved ones impacted by #ProstateCancer to learn about the role of exercise in prostate cancer care, as well as how to best navigate educational and supportive resources: prostatesummit.org #NYCProstateSummit
0
2
3
299
Chris Barbieri retweeted
Reasonable precis of some of my work
You omitted another relevant bit though
The TRANSFORM screening RCT (that I am Chief Investigator for) in which focal therapy is mandated in the screening arms (n=150-300K) (£60M from @ProstateUK & UK National Institute for Health Research
You omitted another relevant bit though
The TRANSFORM screening RCT (that I am Chief Investigator for) in which focal therapy is mandated in the screening arms (n=150-300K) (£60M from @ProstateUK & UK National Institute for Health Research
@FocalSocietys@LondonProstate1 me if I’m wrong or missing anything as I wish to have a good understanding of the RCTs in this space
IP4-CHRONOS-A
Focal HIFU/cryo vs surgery/RT
Closed after pilot failed its feasibility criterion
IP17-APOLLO
Focal therapy ± 3 months neoadjuvant apalutamide
Does not establish focal therapy vs radical therapy
CHRONOS-B
Focal therapy alone vs focal + short neoadjuvant hormonal manipulation
Closed pilot. Feasible, but again not FT vs standard definitive treatment
IP2-ATLANTA
In de novo mHSPC: SOC vs ablative prostate treatment vs radical local therapy, with MDT strategies
Fascinating, but this is cytoreduction in metastatic disease, not a test of focal therapy as definitive localized therapy
PART
Partial ablation vs radical treatment
The most important UK RCT, but Ahmed is not the chief investigator
For partial ablation, the current protocol can allow a repeat focal ablation before declaring failure.
So, is there an RCT he is running that compares FT to definitive treatment?
Very interested to learn more if so or be corrected if I’m off the mark.
Thanks in advance and for all of the hard work!
1
5
16
5,032
Chris Barbieri retweeted
@FocalSocietys@LondonProstate1 me if I’m wrong or missing anything as I wish to have a good understanding of the RCTs in this space
IP4-CHRONOS-A
Focal HIFU/cryo vs surgery/RT
Closed after pilot failed its feasibility criterion
IP17-APOLLO
Focal therapy ± 3 months neoadjuvant apalutamide
Does not establish focal therapy vs radical therapy
CHRONOS-B
Focal therapy alone vs focal + short neoadjuvant hormonal manipulation
Closed pilot. Feasible, but again not FT vs standard definitive treatment
IP2-ATLANTA
In de novo mHSPC: SOC vs ablative prostate treatment vs radical local therapy, with MDT strategies
Fascinating, but this is cytoreduction in metastatic disease, not a test of focal therapy as definitive localized therapy
PART
Partial ablation vs radical treatment
The most important UK RCT, but Ahmed is not the chief investigator
For partial ablation, the current protocol can allow a repeat focal ablation before declaring failure.
So, is there an RCT he is running that compares FT to definitive treatment?
Very interested to learn more if so or be corrected if I’m off the mark.
Thanks in advance and for all of the hard work!
IP4-CHRONOS-A
Focal HIFU/cryo vs surgery/RT
Closed after pilot failed its feasibility criterion
IP17-APOLLO
Focal therapy ± 3 months neoadjuvant apalutamide
Does not establish focal therapy vs radical therapy
CHRONOS-B
Focal therapy alone vs focal + short neoadjuvant hormonal manipulation
Closed pilot. Feasible, but again not FT vs standard definitive treatment
IP2-ATLANTA
In de novo mHSPC: SOC vs ablative prostate treatment vs radical local therapy, with MDT strategies
Fascinating, but this is cytoreduction in metastatic disease, not a test of focal therapy as definitive localized therapy
PART
Partial ablation vs radical treatment
The most important UK RCT, but Ahmed is not the chief investigator
For partial ablation, the current protocol can allow a repeat focal ablation before declaring failure.
So, is there an RCT he is running that compares FT to definitive treatment?
Very interested to learn more if so or be corrected if I’m off the mark.
Thanks in advance and for all of the hard work!
2
7
37
8,221
Chris Barbieri retweeted
@dr_coopsa@DrSpratticus alludes to this "belief" that focal therapy has a role despite the absence of evidence that it benefits patients. I’m not a biased opinion—If it worked, I would very gladly offer it. But there is no quality evidence that it does.
The argument that the evidence is lacking because focal therapy is too new is stale. It has been around for decades. The limited evidence we do have I find concerning.
Why would we subject patients to an unproven treatment that carries a very real risk of long-term harm?
Unfortunately, much of the literature from focal therapy’s proponents has devolved into disingenuous direct-to-patient marketing. As a field, we need to do better than embrace something because it is marketed as “NEW AND IMPROVED—now with fewer side effects!”
Cancer patients who put their trust in us deserve better than that.
@DrSpratticus @SBasourakos
The argument that the evidence is lacking because focal therapy is too new is stale. It has been around for decades. The limited evidence we do have I find concerning.
Why would we subject patients to an unproven treatment that carries a very real risk of long-term harm?
Unfortunately, much of the literature from focal therapy’s proponents has devolved into disingenuous direct-to-patient marketing. As a field, we need to do better than embrace something because it is marketed as “NEW AND IMPROVED—now with fewer side effects!”
Cancer patients who put their trust in us deserve better than that.
@DrSpratticus @SBasourakos
2
8
20
2,059
Chris Barbieri retweeted
Phase 1 #RTIRE: focal IRE + reduced-dose RT (32.5 Gy/5 fx) for intermediate risk prostate cancer:
✅ 10/10 negative biopsies at 12 mo
✅ No grade 3–5 AEs
Promising, NOT definitive.
pubs.rsna.org/doi/epdf/10.11…
Next: phase 2 data final report in 42 patients → ongoing randomized #IRRADIANT trial (cancer.gov/research/parti…).
✅ 10/10 negative biopsies at 12 mo
✅ No grade 3–5 AEs
Promising, NOT definitive.
pubs.rsna.org/doi/epdf/10.11…
Next: phase 2 data final report in 42 patients → ongoing randomized #IRRADIANT trial (cancer.gov/research/parti…).
1
9
32
7,697
Chris Barbieri retweeted
👏 Congratulations to our 15 Research Scholar Awardees!
The awardees are rising researchers advancing earlier detection, more personalized therapies and improved outcomes across urologic disease. This year’s awardees represent a diverse range of research areas—from cancer intelligence to pediatric care and infection prevention.
🔗 Click to learn more about the program and the awardees: bit.ly/4r5ABpA
The awardees are rising researchers advancing earlier detection, more personalized therapies and improved outcomes across urologic disease. This year’s awardees represent a diverse range of research areas—from cancer intelligence to pediatric care and infection prevention.
🔗 Click to learn more about the program and the awardees: bit.ly/4r5ABpA
1
13
43
12,454
Chris Barbieri retweeted
Congratulations to our residents for being awarded the bronze medal at the @AmerUrological National Residency Abstract Olympics!🏆
This outstanding achievement recognizes the remarkable work of our residents which is reflected in their many abstracts being presented at #AUA26!
This outstanding achievement recognizes the remarkable work of our residents which is reflected in their many abstracts being presented at #AUA26!
Congratulations to the newly awarded 2026 National Residency Abstract Olympics winners! 🏆
@CleClinicUro @NM_Urology @WCMUrology
#AUA26
1
9
41
3,505
Chris Barbieri retweeted
I could not have done it better! @TylerSbrt7 gets all the key messages across for the ProtecT surgical review 👇🏻 Next stop: looking at 20-year outcomes in more specimens AND doubling down on efforts to improve early detection of high-grade, T3b cribriform disease 🔬🩻
🚨The sequel is here!! The other 👞 drops.
Cribriform morphology in ProtecT — now in prostatectomy specimens
#ProstateCancer #radonc #UroSoMe
@urotoday @APCCC_Lugano @PCF_Science @OncoAlert
🧵1️⃣
1
7
23
3,483
Chris Barbieri retweeted
Join us in congratulating our 2026 Match Class!🎉
We are thrilled to welcome Juan Angulo‑Lozano, Allison Booher, Nikhil Pramod and Evan Suzman to the team. We can’t wait to see all that each of you will accomplish throughout your residency!
#UroMatch26 #UrologyMatch #MatchDay
We are thrilled to welcome Juan Angulo‑Lozano, Allison Booher, Nikhil Pramod and Evan Suzman to the team. We can’t wait to see all that each of you will accomplish throughout your residency!
#UroMatch26 #UrologyMatch #MatchDay
7
18
149
24,453
Chris Barbieri retweeted
Our take-home finding is that ctDNA detectability was strongly correlated with metastatic - but not local - disease recurrence. A big thanks to patients, families, research teams, colleagues, and funding sources who made this work possible!
3
11
44
8,307
Chris Barbieri retweeted
Happy to share new work from our team now available online @CCR_AACR. We profiled plasma ctDNA dynamics in patients with muscle-invasive bladder cancer (MIBC) treated with bladder-sparing trimodality therapy (TMT)...
doi.org/10.1158/1078-0…
doi.org/10.1158/1078-0…
5
13
41
2,934
Chris Barbieri retweeted
Hear from Lina Posada Calderon, MD, PGY‑6 chief resident, as she breaks down the team’s latest research on RCC associated with germline BAP1 tumor predisposition syndrome in a @UrologyTimes feature⏬
WATCH🎥: Lina Posada Calderon, MD, (@LinaPosadaCald) highlights key takeaways from a recent study examining germline BAP1-associated renal cell carcinoma. @WCMUrology urologytimes.com/view/lina-posa…
0
2
8
1,993
Chris Barbieri retweeted
WATCH🎥: Lina Posada Calderon, MD, (@LinaPosadaCald) highlights key takeaways from a recent study examining germline BAP1-associated renal cell carcinoma. @WCMUrology urologytimes.com/view/lina-posa…
0
4
9
3,236